392 trials
Covid19
Primary: Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1 — 6; 0 Participants
NAFLD
Primary: Change in Hepatic Fat Fraction — -3.0; 0.3 Percent (Hepatic fat fraction, percent)
Contraception
Primary: Number of Participants That Were Appropriately Screened for Contraceptive Use — 155; 136; 49; 51 Participants
Glioblastoma
Primary: Concentration of Ixazomib in Tumor Tissue — 7.88; 2.03; 4.17; 2.70 ng/g
Social Anxiety Disorder
Primary: Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) — 12.1; 19.6 units on a scale
Essential Tremor
Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
Pain, Postoperative · Analgesia
Primary: Postoperative Pain, as Measured by Wong-Baker Facial Rating Pain Scale ,After Routine Dental Treatment — 20; 20; 7; 11 Participants
Sleep
Primary: Sleep Efficiency — 77.6; 76.8 percentage of time in bed sleeping
Carcinoma, Hepatocellular · Metastatic Colorectal Cancer
Primary: To Assess the Safety and Tolerability of Treatment With BTG-002814 — 8; 4 Participants
Obesity
Primary: To Determine Whether Oral Administration of Celebrex to Obese Women Will Reduce the PGE-M in Urine
Alcohol Use Disorder
Primary: Number of Alcohol Drinks Chosen — 3.1; 2.8; 3.8 Number of Alcohol Drinks Chosen
Keloid
Primary: Change in Keloid Surface Area — 0.455; -0.039 cm2
Pain Control
Primary: Pain Score — 17; 17 score on a scale
Nicotine Dependence
Primary: The Reinforcing Drug Effects Will be Measured With the Drug Effects Questionnaire (DEQ). — 43.18; 26.22; 25.20; 56.00 units on a scale